Abstract
5-aminolevulinic acid (5-ALA) is a prodrug that results in the fluorescence of high-grade gliomas relative to the surrounding brain parenchyma. 5-ALA has been increasingly utilized in fluorescence-guided surgery for these tumors, and its intraoperative use has been associated with a significantly improved extent of resection and progression-free survival. This review outlines the growing body of evidence that has culminated in the recent Food and Drug Administration approval of 5-ALA, as well as emerging applications for this agent.
| Original language | English |
|---|---|
| Pages (from-to) | 356-361 |
| Number of pages | 6 |
| Journal | Journal of Surgical Oncology |
| Volume | 118 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1 Aug 2018 |
| Externally published | Yes |
Keywords
- 5-aminolevulinic acid (5-ALA)
- glioblastoma multiforme (GBM)
- photodynamic therapy